Search Result
Results for "
1,4,7-triazacyclononane-1,4,7-triacetic acid
" in MedChemExpress (MCE) Product Catalog:
5
Isotope-Labeled Compounds
| Cat. No. |
상품명 |
Target |
연구분야 |
Chemical Structure |
-
- HY-P0014
-
-
-
- HY-P3462
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
-
- HY-P3462A
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
-
- HY-P10272
-
|
PTG-300
|
Ferroportin
|
Others
|
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
-
-
- HY-P1934
-
|
Cyclo(phenylalanylprolyl); A-64863
|
HCV
Bacterial
Antibiotic
Reactive Oxygen Species (ROS)
|
Infection
|
|
Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) is a quorum-sensing molecule of Vibrio vulnificus that specifically interacts with RIG-I, inhibiting RIG-I polyubiquitination, suppressing IRF-3 activation, and reducing type I interferon production. Cyclo(Phe-Pro) enhances susceptibility to HCV and influenza virus and also alleviates plant aluminum toxicity stress. The mechanism of Cyclo(Phe-Pro) involves the regulation of host immune signaling pathways, bacterial virulence gene expression, and plant antioxidant systems, making it a promising candidate for research in viral infections, bacterial virulence regulation, and agricultural stress resistance .
|
-
-
- HY-P2231
-
|
MEDI0382
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
-
- HY-P2231A
-
|
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
-
- HY-P3291
-
|
ZP7570
|
GCGR
|
Metabolic Disease
|
|
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
|
-
-
- HY-P10218
-
|
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
|
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
-
- HY-P0014S1
-
|
|
Isotope-Labeled Compounds
GLP Receptor
GCGR
|
Others
|
|
Liraglutide- 13C6, 15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
-
- HY-P10271
-
|
NNC0090-2746; MAR709; RO6811135
|
GLP Receptor
|
Metabolic Disease
|
|
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
|
-
-
- HY-W006212
-
|
1,4,7-triazacyclononane
|
Biochemical Assay Reagents
|
Others
|
|
1,4,7-Triazonane (1,4,7-Triazacyclononane), an intermediate in the synthesis of 1,4,7-trifunctionalized derivatives, is a possible reagent for compleximetric titrations with high cation-binding selectivity .
|
-
-
- HY-W015424
-
-
-
- HY-W016012
-
|
H-Glu-Glu-OH; Glutamyl-glutamic acid
|
Amino Acid Derivatives
|
Others
|
|
Glu-Glu is a glutamic acid derivative containing amino and carboxyl groups. Glu-Glu is an analogs of acidic tripeptide and can contribute to calcium absorption .
|
-
-
- HY-107245
-
|
|
Estrogen Receptor/ERR
Sirtuin
RUNX
|
Metabolic Disease
|
|
Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP) .
|
-
-
- HY-P10218A
-
|
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
|
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
-
- HY-P0014B
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .
|
-
-
- HY-P3143
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
-
- HY-P11273
-
-
-
- HY-P11290
-
-
-
- HY-153476A
-
|
|
GLP Receptor
GCGR
|
Inflammation/Immunology
|
|
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-153476
-
|
|
GCGR
GLP Receptor
|
Inflammation/Immunology
|
|
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-P10579
-
123B9
1 Publications Verification
|
Ephrin Receptor
|
Cancer
|
|
123B9, a tumor-homing agent, is a potent and selective EphA2 agonist with a Kd value of 4.0 μM. 123B9 selectively targets the EphA2 tyrosine kinase receptor ligand-binding domain. 123B9 does not appreciably inhibit the ligand binding domains of the most closely related EphA3 and EphA4 receptors .
|
-
-
- HY-P10426
-
|
|
HIF/HIF Prolyl-Hydroxylase
VEGFR
|
Cancer
|
|
cyclo(CLLFVY) is an inhibitor for hypoxia inducible factor-1 (HIF-1), with IC50 of 19 μM (in U2OS) and 16 μM (in MCF-7). cyclo(CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo(CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers .
|
-
-
- HY-75564
-
|
|
Endogenous Metabolite
|
Cancer
|
|
Cyclo(Ala-Gly), a metabolite of a mangrove endophytic fungus, Penicillium thomi, exhibits cytotoxicity against A549, HepG2 and HT29 cells. The IC50 values range from 9.5 to 18.1 μM .
|
-
-
- HY-P10341
-
|
|
GCGR
|
Metabolic Disease
|
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
-
- HY-117141
-
-
-
- HY-W008559
-
-
-
- HY-169089
-
|
|
Drug Derivative
|
Cancer
|
|
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .
|
-
-
- HY-P10563
-
|
BHV-1100
|
CD38
|
Cancer
|
|
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
|
-
-
- HY-P5524A
-
|
Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid hydrochloride; γ-D-glutamyl-meso-diaminopimelic acid hydrochloride
|
NOD-like Receptor (NLR)
|
Others
|
|
C12-iE-DAP hydrochloride is the hydrochloride salt form of C12-iE-DAP (HY-P5524). C12-iE-DAP hydrochloride is a biologically active peptide that has agonistic effects on NOD1 .
|
-
-
- HY-P10053
-
|
|
Phospholipase
|
Metabolic Disease
|
|
sPLA2-IIA Inhibitor is a cyclic pentapeptide analog of FLSYK (cyclic 2-Nal-Leu-Ser-2-Nal-Arg (c2)), that binds to hGIIA (human IIA phospholipase A2) and inhibits its hydrolytic ability. sPLA2 is a member of the esterase superfamily that catalyzes the hydrolysis of the ester bond at the sn-2 position of glycerophospholipids, releasing free fatty acids such as arachidonic acid and lysophospholipids .
|
-
-
- HY-30216AR
-
|
α-Hydroxyisocaproic acid (Standard)
|
Endogenous Metabolite
Reference Standards
|
Others
|
|
Leucic acid (Standard) is the analytical standard of Leucic acid. This product is intended for research and analytical applications. Leucic acid is an amino acid metabolite .
|
-
-
- HY-W048209
-
|
|
Amino Acid Derivatives
|
Others
|
|
Fmoc-Lys(Palmitoyl)-OH is a Fmoc-amino acid with long alkyl chains. Fmoc-Lys(Palmitoyl)-OH can be used for peptide synthesis .
|
-
-
- HY-W016424
-
-
-
- HY-P10222
-
|
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 14.5 and 10.2 μM, respectively .
|
-
-
- HY-P11233
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .
|
-
-
- HY-P0014AS
-
-
-
- HY-P5524
-
|
Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid; γ-D-glutamyl-meso-diaminopimelic acid
|
NOD-like Receptor (NLR)
|
Others
|
|
C12-iE-DAP (Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid) is a biological active peptide. (a lauroyl (C12) group to the glutamic residue of iE-DAP , NOD1 agonist)
|
-
-
- HY-W040417
-
|
|
PI3K
|
Others
|
|
Boc-L-cyclobutylglycine is a Boc-protected L-cyclic amino acid and synthetic intermediate in the preparation of purinyl quinazolinone PI3Kδ inhibitors .
|
-
-
- HY-P0041A
-
-
-
- HY-169089A
-
|
|
Drug Derivative
|
Cancer
|
|
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .
|
-
-
- HY-P1614
-
-
-
- HY-P0014A
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .
|
-
-
- HY-P10318
-
|
|
GLP Receptor
|
Endocrinology
|
|
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
|
-
-
- HY-P3143A
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
-
- HY-P0014S2
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
Liraglutide- 13C6, 15 TFA is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
-
- HY-113560
-
-
-
- HY-P1162
-
-
-
- HY-P11243
-
|
|
Ephrin Receptor
|
Neurological Disease
|
|
EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .
|
-
- HY-P10910
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Vensemaglutide is the agonist for glucagon-like peptide 1 (GLP-1) receptor. Vensemaglutide can be used in research of diabetes or other metabolic disorders .
|
-
- HY-P10775
-
|
|
Peptide-Drug Conjugates (PDCs)
MMP
|
Cancer
|
|
BT1769 is a MT1-MMP-targeted (KD = 3.35 nM) Bicycle toxin conjugate. BT1769 can be used in the study for osteosarcoma. BT1769 consists of a novel bicyclic targeting peptide that selectively binds MT1-MMP; a cytotoxin MMAE; and an enzymatically cleavable dipeptide linker .
|
-
- HY-106224AS1
-
|
Hypocretin-1-13C18,15N3 (human, rat, mouse) TFA
|
Isotope-Labeled Compounds
Orexin Receptor (OX Receptor)
|
Neurological Disease
|
|
Orexin A- 13C18, 15N3 (human, rat, mouse) ((Hypocretin-1- 13C18, 15N3 (human, rat, mouse)) TFA is the 13C- and 15N-labeled Orexin A (human, rat, mouse) (HY-106224). Orexin A (human, rat, mouse) (Hypocretin-1 (human, rat, mouse)), a 33 amino acid excitatory neuropeptide, orchestrates diverse central and peripheral processes. Orexin A (human, rat, mouse) binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) has a role in the regulation of feeding behavior. Orexin A (human, rat, mouse) is an effective anti-nociceptive and anti-hyperalgesic agent in mice and rats .
|
-
- HY-P11431
-
-
- HY-W037451
-
|
|
Amino Acid Derivatives
|
Others
|
|
Methyl L-leucinate, methyl ester of L-leucine, is an alpha-amino acid ester. Methyl L-leucinate is a derivative of methyl ester and L-leucine, a class of compounds containing both amino and carboxyl groups in the molecule .
|
-
- HY-41631
-
|
(S)-Ethyl-N-Boc-pyroglutamate
|
Amino Acid Derivatives
Drug Intermediate
|
Others
|
|
Boc-Pyr-Oet ((S)-Ethyl-N-Boc-pyroglutamate) is a derivative of L-Pyroglutamic acid (HY-76082). Boc-Pyr-Oet can be used for the synthesis of agents or other compounds.
|
-
- HY-W041076
-
-
- HY-77635
-
-
- HY-W051612
-
|
|
Amino Acid Derivatives
|
Others
|
|
DL-Propargylglycine hydrochloride is a Glycine (HY-Y0966) derivative. DL-Propargylglycine hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .
|
-
- HY-W836186
-
|
Cyclo(alanine-leucine)
|
Bacterial
|
Others
|
|
Cyclo(Leu-Ala) (Cyclo(alanine-leucine)) is an antimicrobial compound isolated from microorganisms and has antimicrobial activity against some plant pathogens together with other compounds.
|
-
- HY-P5033
-
|
|
Bacterial
|
Cancer
|
Cyclo(Gly-His) is a liposome-encapsulated cyclic dipeptide with antimicrobial and anticancer activity. Cyclo(Gly-His) has cytotoxicity for HeLa and MCF-7 cell with IC50 values of 1.699 mM and 0.358 mM, respectively. Cyclo(Gly-His) can be used for the research of drug delivery systems .
|
-
- HY-P11424
-
|
|
Integrin
|
Cancer
|
|
Cyclo(GRGDSPA) is a cyclic RGD peptide targeting αvβ3 integrin. Cyclo(GRGDSPA) reduces the formation of colonies in mice injected with B16-FE7 melanoma cells. Cyclo(GRGDSPA) can be used for melanoma research .
|
-
- HY-109166
-
-
- HY-P10200
-
|
|
Bacterial
|
Infection
|
|
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
|
-
- HY-P10876
-
|
|
Amyloid-β
|
Neurological Disease
|
|
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
|
-
- HY-P0041
-
-
- HY-P10869
-
dCNP
1 Publications Verification
|
Natriuretic Peptide Receptor (NPR)
|
Inflammation/Immunology
Cancer
|
|
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
|
-
- HY-P5161
-
-
- HY-P5161A
-
-
- HY-P11279
-
|
|
GLP Receptor
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC50 values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes .
|
-
- HY-W112678
-
|
Benzene-1,3,5-triacetic acid
|
MOFs
|
Others
|
|
2,2',2''-(Benzene-1,3,5-triyl)triacetic acid (Benzene-1,3,5-triacetic acid) is a metal-organic framework (MOF).
|
-
- HY-P2595
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .
|
-
- HY-P10881
-
-
- HY-142953
-
-
- HY-P10052
-
|
|
VEGFR
|
Cancer
|
|
CBO-P11 specifically binds to receptor of VEGFR-2 and is used as targeting ligand for tumor angiogenesis. CBO-P11 is modified with a nearinfrared cyanine dye bearing an alkyne function, allowing both “click” coupling on azido-modified nanoparticles and fluorescence labelling .
|
-
- HY-W145762
-
-
- HY-W291634
-
-
- HY-W016330
-
-
- HY-W015424R
-
-
- HY-P4201
-
|
|
Vasopressin Receptor
|
Cardiovascular Disease
|
|
JKC 301 is a selective Endothelin A receptor antagonist. JKC 301 attenuates the pressor effects of nicotine in rats. JKC 301 can be used to study cardiovascular disease caused by smoking .
|
-
- HY-W075170
-
|
|
MOFs
|
Others
|
|
2,2',2''-(Benzene-1,3,5-triyltris(oxy))triacetic acid is a metal-organic framework (MOF).
|
-
- HY-P11759
-
|
|
Drug Derivative
|
Cancer
|
|
Myr-transportan-Cys is a derivative of the cell-penetrating peptide Transportan (HY-P1732), and its conjugated myristoyl group (Myr) enhances the interaction between the peptide and cell membranes. Myr-transportan-Cys integrates three key delivery functions: nucleic acid condensation, cell penetration, and endosomal escape. Myr-transportan-Cys can form immunostimulatory tandem peptide nanocomplexes (iTPNCs) for encapsulating and delivering immunostimulatory oligonucleotide cargos to tumors .
|
-
- HY-N17580
-
|
|
Renin
|
Cardiovascular Disease
|
|
Lyciumin D acts as an angiotensin-converting enzyme inhibitor and renin inhibitor. Lyciumin D can be used for the research of hypertension .
|
-
- HY-P11604
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF is a cell-permeable and internalizable PTPN1/2 inhibitor, with IC50 values of 107.6 nM and 3375 nM, respectively. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF restores insulin signaling in HepG2 cells. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF achieves glycemic control in db/db diabetic mice. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF can be used in the research of type 2 diabetes .
|
-
- HY-P11625
-
|
|
RXFP Receptor
|
Cardiovascular Disease
|
|
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
|
-
- HY-P11586
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity .
|
-
- HY-P11576
-
|
|
Integrin
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Cyclic αvβ6 (Compound c(FRGDLAFp(NMe)K)) is a αvβ6-integrin-specific cyclic nonapeptide. Cyclic αvβ6 can be coupled with 68Ga-labeled monomeric triazacyclononane-triphosphinate (TRAP). Cyclic αvβ6 can be used in PET imaging studies for cancers including head and neck cancer and pancreatic cancer .
|
-
- HY-P11769
-
|
|
CGRP Receptor
|
Cancer
|
|
RM2 is a GRPr antagonist. RM2 selectively binds to GRPr, blocks agonist-induced receptor internalization, and inhibits agonist-triggered intracellular calcium mobilization. RM2 can be used in studies related to prostate cancer .
|
-
- HY-N18041
-
|
|
Drug Derivative
|
Others
|
|
Pseudostellarin E is a proline-rich, caryophyllaceous cyclopeptide present in the roots of Pseudostellaria heterophylla. Pseudostellarin E can be synthesized by overexpressing its precursor gene prePhPE in the leaves of Nicotiana benthamiana .
|
-
- HY-P11751A
-
|
|
Endogenous Metabolite
Endothelin Receptor
|
Cardiovascular Disease
Infection
|
|
RES-701-3 peptide TFA is a class II lasso peptide. RES-701-3 peptide TFA can be isolated from the fermentation broth of Streptomyces species. RES-701-3 peptide TFA potently inhibits the binding of ET-1 to ETB, with an IC50 of approximately 5-10 nM. RES-701-3 peptide TFA is applicable to research related to systemic hypertension, myocardial infarction, and myocardial ischemia .
|
-
- HY-P11627
-
|
|
Endogenous Metabolite
|
Others
|
|
Cyclo(Pro-Hyp) is a collagen-derived cyclic dipeptide, and its related collagen breakdown product Gly-Pro-Hyp promotes the growth of skin fibroblasts and participates in tissue reconstruction, exhibiting biological activity.
|
-
- HY-P11626
-
|
|
Collagen
|
Metabolic Disease
|
|
Cyclo(Ala-Hyp) is an orally effective collagen-derived hydroxyproline-containing cyclic dipeptide that can be isolated from the culture supernatant of Lactobacillus plantarum. Cyclo(Ala-Hyp) has an AUC0-6h of 2.350 μg/mL·h, significantly higher than traditional collagen oligopeptides. Cyclo(Ala-Hyp) can be used in research related to liver and kidney function protection, skin care, and joint health.
|
-
| Cat. No. |
상품명 |
Target |
Research Area |
-
- HY-P0014
-
-
- HY-P3462
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
- HY-P3462A
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
- HY-P10272
-
|
PTG-300
|
Ferroportin
|
Others
|
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
-
- HY-P1934
-
|
Cyclo(phenylalanylprolyl); A-64863
|
HCV
Bacterial
Antibiotic
Reactive Oxygen Species (ROS)
|
Infection
|
|
Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) is a quorum-sensing molecule of Vibrio vulnificus that specifically interacts with RIG-I, inhibiting RIG-I polyubiquitination, suppressing IRF-3 activation, and reducing type I interferon production. Cyclo(Phe-Pro) enhances susceptibility to HCV and influenza virus and also alleviates plant aluminum toxicity stress. The mechanism of Cyclo(Phe-Pro) involves the regulation of host immune signaling pathways, bacterial virulence gene expression, and plant antioxidant systems, making it a promising candidate for research in viral infections, bacterial virulence regulation, and agricultural stress resistance .
|
-
- HY-P2231
-
|
MEDI0382
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P2231A
-
|
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P3291
-
|
ZP7570
|
GCGR
|
Metabolic Disease
|
|
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
|
-
- HY-P10218
-
|
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
|
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-P0014S1
-
|
|
Isotope-Labeled Compounds
GLP Receptor
GCGR
|
Others
|
|
Liraglutide- 13C6, 15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
- HY-P10271
-
|
NNC0090-2746; MAR709; RO6811135
|
GLP Receptor
|
Metabolic Disease
|
|
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
|
-
- HY-W015424
-
-
- HY-W016012
-
|
H-Glu-Glu-OH; Glutamyl-glutamic acid
|
Amino Acid Derivatives
|
Others
|
|
Glu-Glu is a glutamic acid derivative containing amino and carboxyl groups. Glu-Glu is an analogs of acidic tripeptide and can contribute to calcium absorption .
|
-
- HY-107245
-
|
|
Estrogen Receptor/ERR
Sirtuin
RUNX
|
Metabolic Disease
|
|
Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP) .
|
-
- HY-P1936
-
|
|
Peptides
|
Others
|
|
Cyclo(Gly-L-Pro) is a Alkaloids product that can be isolated from the roots of Panax notoginseng (Burk.)F.H.Chen .
|
-
- HY-P10218A
-
|
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
|
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-P0014B
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .
|
-
- HY-P3143
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-P11273
-
-
- HY-P11290
-
-
- HY-153476A
-
|
|
GLP Receptor
GCGR
|
Inflammation/Immunology
|
|
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
|
-
- HY-153476
-
|
|
GCGR
GLP Receptor
|
Inflammation/Immunology
|
|
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
|
-
- HY-P10579
-
123B9
1 Publications Verification
|
Ephrin Receptor
|
Cancer
|
|
123B9, a tumor-homing agent, is a potent and selective EphA2 agonist with a Kd value of 4.0 μM. 123B9 selectively targets the EphA2 tyrosine kinase receptor ligand-binding domain. 123B9 does not appreciably inhibit the ligand binding domains of the most closely related EphA3 and EphA4 receptors .
|
-
- HY-P10426
-
|
|
HIF/HIF Prolyl-Hydroxylase
VEGFR
|
Cancer
|
|
cyclo(CLLFVY) is an inhibitor for hypoxia inducible factor-1 (HIF-1), with IC50 of 19 μM (in U2OS) and 16 μM (in MCF-7). cyclo(CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo(CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers .
|
-
- HY-75564
-
|
|
Endogenous Metabolite
|
Cancer
|
|
Cyclo(Ala-Gly), a metabolite of a mangrove endophytic fungus, Penicillium thomi, exhibits cytotoxicity against A549, HepG2 and HT29 cells. The IC50 values range from 9.5 to 18.1 μM .
|
-
- HY-P10341
-
|
|
GCGR
|
Metabolic Disease
|
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
- HY-117141
-
-
- HY-W008559
-
-
- HY-131115
-
-
- HY-169089
-
|
|
Drug Derivative
|
Cancer
|
|
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .
|
-
- HY-P10563
-
|
BHV-1100
|
CD38
|
Cancer
|
|
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
|
-
- HY-P5524A
-
|
Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid hydrochloride; γ-D-glutamyl-meso-diaminopimelic acid hydrochloride
|
NOD-like Receptor (NLR)
|
Others
|
|
C12-iE-DAP hydrochloride is the hydrochloride salt form of C12-iE-DAP (HY-P5524). C12-iE-DAP hydrochloride is a biologically active peptide that has agonistic effects on NOD1 .
|
-
- HY-P10053
-
|
|
Phospholipase
|
Metabolic Disease
|
|
sPLA2-IIA Inhibitor is a cyclic pentapeptide analog of FLSYK (cyclic 2-Nal-Leu-Ser-2-Nal-Arg (c2)), that binds to hGIIA (human IIA phospholipase A2) and inhibits its hydrolytic ability. sPLA2 is a member of the esterase superfamily that catalyzes the hydrolysis of the ester bond at the sn-2 position of glycerophospholipids, releasing free fatty acids such as arachidonic acid and lysophospholipids .
|
-
- HY-30216AR
-
|
α-Hydroxyisocaproic acid (Standard)
|
Endogenous Metabolite
Reference Standards
|
Others
|
|
Leucic acid (Standard) is the analytical standard of Leucic acid. This product is intended for research and analytical applications. Leucic acid is an amino acid metabolite .
|
-
- HY-W048209
-
|
|
Amino Acid Derivatives
|
Others
|
|
Fmoc-Lys(Palmitoyl)-OH is a Fmoc-amino acid with long alkyl chains. Fmoc-Lys(Palmitoyl)-OH can be used for peptide synthesis .
|
-
- HY-W016424
-
-
- HY-P10222
-
|
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 14.5 and 10.2 μM, respectively .
|
-
- HY-P11233
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .
|
-
- HY-P0014AS
-
-
- HY-P5524
-
|
Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid; γ-D-glutamyl-meso-diaminopimelic acid
|
NOD-like Receptor (NLR)
|
Others
|
|
C12-iE-DAP (Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid) is a biological active peptide. (a lauroyl (C12) group to the glutamic residue of iE-DAP , NOD1 agonist)
|
-
- HY-W040417
-
|
|
PI3K
|
Others
|
|
Boc-L-cyclobutylglycine is a Boc-protected L-cyclic amino acid and synthetic intermediate in the preparation of purinyl quinazolinone PI3Kδ inhibitors .
|
-
- HY-P5751
-
|
|
Peptides
|
Others
|
|
Cyclo(Ile-Val) is a Alkaloids product that can be isolated from the roots of Panax notoginseng (Burk.)F.H.Chen .
|
-
- HY-P0041A
-
-
- HY-169089A
-
|
|
Drug Derivative
|
Cancer
|
|
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .
|
-
- HY-P1614
-
-
- HY-P0014A
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .
|
-
- HY-P10318
-
|
|
GLP Receptor
|
Endocrinology
|
|
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
|
-
- HY-P3143A
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-P0014S2
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
Liraglutide- 13C6, 15 TFA is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
- HY-113560
-
- HY-P1162
-
- HY-P11243
-
|
|
Ephrin Receptor
|
Neurological Disease
|
|
EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .
|
- HY-P10910
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Vensemaglutide is the agonist for glucagon-like peptide 1 (GLP-1) receptor. Vensemaglutide can be used in research of diabetes or other metabolic disorders .
|
- HY-P10775
-
|
|
Peptide-Drug Conjugates (PDCs)
MMP
|
Cancer
|
|
BT1769 is a MT1-MMP-targeted (KD = 3.35 nM) Bicycle toxin conjugate. BT1769 can be used in the study for osteosarcoma. BT1769 consists of a novel bicyclic targeting peptide that selectively binds MT1-MMP; a cytotoxin MMAE; and an enzymatically cleavable dipeptide linker .
|
- HY-106224AS1
-
|
Hypocretin-1-13C18,15N3 (human, rat, mouse) TFA
|
Isotope-Labeled Compounds
Orexin Receptor (OX Receptor)
|
Neurological Disease
|
|
Orexin A- 13C18, 15N3 (human, rat, mouse) ((Hypocretin-1- 13C18, 15N3 (human, rat, mouse)) TFA is the 13C- and 15N-labeled Orexin A (human, rat, mouse) (HY-106224). Orexin A (human, rat, mouse) (Hypocretin-1 (human, rat, mouse)), a 33 amino acid excitatory neuropeptide, orchestrates diverse central and peripheral processes. Orexin A (human, rat, mouse) binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) has a role in the regulation of feeding behavior. Orexin A (human, rat, mouse) is an effective anti-nociceptive and anti-hyperalgesic agent in mice and rats .
|
- HY-P11431
-
- HY-W037451
-
|
|
Amino Acid Derivatives
|
Others
|
|
Methyl L-leucinate, methyl ester of L-leucine, is an alpha-amino acid ester. Methyl L-leucinate is a derivative of methyl ester and L-leucine, a class of compounds containing both amino and carboxyl groups in the molecule .
|
- HY-41631
-
|
(S)-Ethyl-N-Boc-pyroglutamate
|
Amino Acid Derivatives
Drug Intermediate
|
Others
|
|
Boc-Pyr-Oet ((S)-Ethyl-N-Boc-pyroglutamate) is a derivative of L-Pyroglutamic acid (HY-76082). Boc-Pyr-Oet can be used for the synthesis of agents or other compounds.
|
- HY-W041076
-
- HY-77635
-
- HY-W051612
-
|
|
Amino Acid Derivatives
|
Others
|
|
DL-Propargylglycine hydrochloride is a Glycine (HY-Y0966) derivative. DL-Propargylglycine hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .
|
- HY-W836186
-
|
Cyclo(alanine-leucine)
|
Bacterial
|
Others
|
|
Cyclo(Leu-Ala) (Cyclo(alanine-leucine)) is an antimicrobial compound isolated from microorganisms and has antimicrobial activity against some plant pathogens together with other compounds.
|
- HY-P5033
-
|
|
Bacterial
|
Cancer
|
Cyclo(Gly-His) is a liposome-encapsulated cyclic dipeptide with antimicrobial and anticancer activity. Cyclo(Gly-His) has cytotoxicity for HeLa and MCF-7 cell with IC50 values of 1.699 mM and 0.358 mM, respectively. Cyclo(Gly-His) can be used for the research of drug delivery systems .
|
- HY-P11424
-
|
|
Integrin
|
Cancer
|
|
Cyclo(GRGDSPA) is a cyclic RGD peptide targeting αvβ3 integrin. Cyclo(GRGDSPA) reduces the formation of colonies in mice injected with B16-FE7 melanoma cells. Cyclo(GRGDSPA) can be used for melanoma research .
|
- HY-109166
-
- HY-P10200
-
|
|
Bacterial
|
Infection
|
|
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
|
- HY-P10876
-
|
|
Amyloid-β
|
Neurological Disease
|
|
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
|
- HY-P0041
-
- HY-P4837
-
|
|
Peptides
|
Others
|
|
Ac-Lys-D-Ala-D-lactic acid is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
- HY-P10869
-
dCNP
1 Publications Verification
|
Natriuretic Peptide Receptor (NPR)
|
Inflammation/Immunology
Cancer
|
|
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
|
- HY-P5161
-
- HY-P5161A
-
- HY-P11279
-
|
|
GLP Receptor
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC50 values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes .
|
- HY-P2595
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .
|
- HY-P10381
-
|
|
Peptides
|
Others
|
|
palm11-TTDS-PrRP31 is a strong agonist of GPR10 (EC50: 84 pM). palm11-TTDS-PrRP31 has long-lasting anorexigenic effects .
|
- HY-P10881
-
- HY-142953
-
- HY-P10052
-
|
|
VEGFR
|
Cancer
|
|
CBO-P11 specifically binds to receptor of VEGFR-2 and is used as targeting ligand for tumor angiogenesis. CBO-P11 is modified with a nearinfrared cyanine dye bearing an alkyne function, allowing both “click” coupling on azido-modified nanoparticles and fluorescence labelling .
|
- HY-W145762
-
- HY-W291634
-
- HY-W016330
-
- HY-W015424R
-
- HY-P3040A
-
|
|
Peptides
|
Others
|
|
PHI-27 (rat) TFA is a 27 amino acid peptide.PHI-27 (rat) TFA is used to find peptide hormones and other active peptides .
|
- HY-P4201
-
|
|
Vasopressin Receptor
|
Cardiovascular Disease
|
|
JKC 301 is a selective Endothelin A receptor antagonist. JKC 301 attenuates the pressor effects of nicotine in rats. JKC 301 can be used to study cardiovascular disease caused by smoking .
|
- HY-P11759
-
|
|
Drug Derivative
|
Cancer
|
|
Myr-transportan-Cys is a derivative of the cell-penetrating peptide Transportan (HY-P1732), and its conjugated myristoyl group (Myr) enhances the interaction between the peptide and cell membranes. Myr-transportan-Cys integrates three key delivery functions: nucleic acid condensation, cell penetration, and endosomal escape. Myr-transportan-Cys can form immunostimulatory tandem peptide nanocomplexes (iTPNCs) for encapsulating and delivering immunostimulatory oligonucleotide cargos to tumors .
|
- HY-N17580
-
|
|
Renin
|
Cardiovascular Disease
|
|
Lyciumin D acts as an angiotensin-converting enzyme inhibitor and renin inhibitor. Lyciumin D can be used for the research of hypertension .
|
- HY-P11604
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF is a cell-permeable and internalizable PTPN1/2 inhibitor, with IC50 values of 107.6 nM and 3375 nM, respectively. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF restores insulin signaling in HepG2 cells. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF achieves glycemic control in db/db diabetic mice. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF can be used in the research of type 2 diabetes .
|
- HY-P11625
-
|
|
RXFP Receptor
|
Cardiovascular Disease
|
|
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
|
- HY-P11586
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity .
|
- HY-P11576
-
|
|
Integrin
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Cyclic αvβ6 (Compound c(FRGDLAFp(NMe)K)) is a αvβ6-integrin-specific cyclic nonapeptide. Cyclic αvβ6 can be coupled with 68Ga-labeled monomeric triazacyclononane-triphosphinate (TRAP). Cyclic αvβ6 can be used in PET imaging studies for cancers including head and neck cancer and pancreatic cancer .
|
- HY-P11769
-
|
|
CGRP Receptor
|
Cancer
|
|
RM2 is a GRPr antagonist. RM2 selectively binds to GRPr, blocks agonist-induced receptor internalization, and inhibits agonist-triggered intracellular calcium mobilization. RM2 can be used in studies related to prostate cancer .
|
- HY-N18041
-
|
|
Drug Derivative
|
Others
|
|
Pseudostellarin E is a proline-rich, caryophyllaceous cyclopeptide present in the roots of Pseudostellaria heterophylla. Pseudostellarin E can be synthesized by overexpressing its precursor gene prePhPE in the leaves of Nicotiana benthamiana .
|
- HY-P11709
-
|
cyclo(CLPVASC)
|
Peptides
|
Metabolic Disease
|
|
CLPVASC is a kidney-targeting cyclic peptide that preferentially distributes to kidney tissue, with utility to enhance kidney targeting of nanocarriers.CLPVASC preferentially distributes to the kidney when displayed on PEG-b-PPS micelles. CLPVASC can be used for the research of acute kidney injury .
|
- HY-P11751A
-
|
|
Endogenous Metabolite
Endothelin Receptor
|
Cardiovascular Disease
Infection
|
|
RES-701-3 peptide TFA is a class II lasso peptide. RES-701-3 peptide TFA can be isolated from the fermentation broth of Streptomyces species. RES-701-3 peptide TFA potently inhibits the binding of ET-1 to ETB, with an IC50 of approximately 5-10 nM. RES-701-3 peptide TFA is applicable to research related to systemic hypertension, myocardial infarction, and myocardial ischemia .
|
- HY-P11627
-
|
|
Endogenous Metabolite
|
Others
|
|
Cyclo(Pro-Hyp) is a collagen-derived cyclic dipeptide, and its related collagen breakdown product Gly-Pro-Hyp promotes the growth of skin fibroblasts and participates in tissue reconstruction, exhibiting biological activity.
|
- HY-P11626
-
|
|
Collagen
|
Metabolic Disease
|
|
Cyclo(Ala-Hyp) is an orally effective collagen-derived hydroxyproline-containing cyclic dipeptide that can be isolated from the culture supernatant of Lactobacillus plantarum. Cyclo(Ala-Hyp) has an AUC0-6h of 2.350 μg/mL·h, significantly higher than traditional collagen oligopeptides. Cyclo(Ala-Hyp) can be used in research related to liver and kidney function protection, skin care, and joint health.
|
- HY-P11266
-
|
|
Peptides
|
Cancer
|
|
Phakellistatin 13 is a natural cycloheptapeptide with anti-tumor activity. Phakellistatin 13 exhibits a potent inhibitory effect on liver cancer cells BEL-7404 (ED500 < 0.01 μg/mL). Phakellistatin 13 can be used for research on liver cancer .
|
| Cat. No. |
상품명 |
Category |
Target |
Chemical Structure |
| Cat. No. |
상품명 |
Chemical Structure |
-
- HY-P0014S1
-
|
|
|
Liraglutide- 13C6, 15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
-
- HY-P0014AS
-
|
|
|
Liraglutide-d8 tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
-
- HY-P0014S2
-
|
|
|
Liraglutide- 13C6, 15 TFA is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
-
- HY-106224AS1
-
|
|
|
Orexin A- 13C18, 15N3 (human, rat, mouse) ((Hypocretin-1- 13C18, 15N3 (human, rat, mouse)) TFA is the 13C- and 15N-labeled Orexin A (human, rat, mouse) (HY-106224). Orexin A (human, rat, mouse) (Hypocretin-1 (human, rat, mouse)), a 33 amino acid excitatory neuropeptide, orchestrates diverse central and peripheral processes. Orexin A (human, rat, mouse) binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) has a role in the regulation of feeding behavior. Orexin A (human, rat, mouse) is an effective anti-nociceptive and anti-hyperalgesic agent in mice and rats .
|
-
-
- HY-P11431
-
|
|
|
Cyclo(Gly-Pro) is a cyclic dipeptide. Cyclo(Gly-Pro) can be derived from the Nterminus of the IGF-1. Cyclo(Gly-Pro) attenuates nociceptive behaviour and inflammatory response in mice .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- 상품명:
- Cat. No.:
- 수량:
- MCE Japan Authorized Agent:
